ERBB2 and breast neoplasm: In previous work, we showed that the FID, WID and PID immune subclasses exhibited a reproducible significant prognostic stratification in breast tumors classified as immune benefit-enabled (IBE), consisting mostly of highly proliferative Basal-like, HER2-enriched and Luminal B subtypes, but not in immune benefit-disabled (IBD) tumors defined by a reduced proliferative phenotype (20).